A Phase 2 Study of ABBV-3067 Alone and in Combination With ABBV-2222

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2019
This study will evaluate the safety, tolerability, and efficacy of ABBV‐3067 given alone and in combination with various doses of ABBV‐2222 in adults with Cystic Fibrosis who are homozygous for the F508del mutation.
Epistemonikos ID: fd6acbbdf47548015a8625b85c0851d5551f9c20
First added on: May 22, 2024